Pacira Pharmaceuticals’ bid to expand the use of its pain therapy Exparel has hit a major speed-bump after FDA advisers did not back an extended use as a nerve block after surgery. While the ...

BRISBANE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform ...

Pacira has settled litigation with Germany's Fresenius Kabi and its partners over patents related to Exparel, which reportedly provides pain relief for up to 72 hours after surgery. As part of the ...

The license will permit entry of generic bupivacaine liposome injectable suspension before the July 2, 2044 expiration date of the last-to-expire of Pacira’s Orange Book-listed patents for Exparel.

Shares of Pacira BioSciences climbed after the company said it entered a settlement agreement regarding the patent litigation for Exparel, a local anesthetic administered at the time of surgery.

Shares of Pacira BioSciences PCRX are rising today after the company announced that it has entered into a settlement agreement with Fresenius, Jiangsu Hengrui Pharmaceuticals and eVenus ...

“We remain confident in our EXPAREL intellectual property portfolio and believe this settlement agreement appropriately recognizes the strength of our patents and provides clarity around EXPAREL ...

related to patents for Exparel. As part of the settlement, the parties will file Consent Judgments with the United States Court of Appeals for the Federal Circuit and the United States District ...